Show simple item record

dc.contributor.authorPrice, OH
dc.contributor.authorSpirason, N
dc.contributor.authorRynehart, C
dc.contributor.authorBrown, SK
dc.contributor.authorTodd, A
dc.contributor.authorPeck, H
dc.contributor.authorPatel, M
dc.contributor.authorSoppe, S
dc.contributor.authorBarr, IG
dc.contributor.authorChow, MK
dc.date.accessioned2020-12-14T06:22:02Z
dc.date.available2020-12-14T06:22:02Z
dc.date.issued2020-03-16
dc.identifier.citationPrice, O. H., Spirason, N., Rynehart, C., Brown, S. K., Todd, A., Peck, H., Patel, M., Soppe, S., Barr, I. G. & Chow, M. K. (2020). Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018. COMMUNICABLE DISEASES INTELLIGENCE, 44, https://doi.org/10.33321/cdi.2020.44.16.
dc.identifier.issn0725-3141
dc.identifier.urihttp://hdl.handle.net/11343/254195
dc.description.abstractAs part of its role in the World Health Organization's (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a total of 3993 human influenza-positive samples during 2018. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or hens' eggs for use as potential seasonal influenza vaccine virus candidates. In 2018, influenza A(H1)pdm09 viruses predominated over influenza A(H3) and B viruses, accounting for a total of 53% of all viruses analysed. The majority of A(H1)pdm09, A(H3) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO-recommended vaccine strains for the Southern Hemisphere in 2018. However, phylogenetic analysis indicated that a significant proportion of circulating A(H3) viruses had undergone genetic drift relative to the WHO-recommended vaccine strain for 2018. Of 2864 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, three A(H1)pdm09 viruses showed highly reduced inhibition by oseltamivir, while one B/Victoria virus showed highly reduced inhibition by both oseltamivir and zanamivir.
dc.languageEnglish
dc.publisherAUSTRALIAN GOVERNMENT, DEPT HEALTH & AGEING
dc.titleReport on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018
dc.typeJournal Article
dc.identifier.doi10.33321/cdi.2020.44.16
melbourne.affiliation.departmentMicrobiology and Immunology
melbourne.affiliation.departmentDoherty Institute
melbourne.source.titleCommunicable Diseases Intelligence Quarterly Report
melbourne.source.volume44
melbourne.elementsid1443974
melbourne.openaccess.urlhttp://doi.org/10.33321/cdi.2020.44.16
melbourne.openaccess.statusPublished version
melbourne.contributor.authorBarr, Ian
melbourne.contributor.authorRynehart, Cleve
dc.identifier.eissn1445-4866
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record